NCT06299748: A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.

Sponsor: argenx. Phase: . Conditions: Myasthenia Gravis, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy